TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10693902

Group type: EXPERIMENTAL
Intervention: Domiciliary monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-hospital monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Within-subject differences
Number of subjects: 0
Study: 8863869

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) infusions 1 g kg‐1 (n = 23)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone pulse therapy (MPPT) 30 mg kg‐1 (n = 20)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone pulse therapy (MPPT)
Number of subjects: 43
Study: 1480736

Group type: EXPERIMENTAL
Intervention: HAL DIRS‐C (Drug Impairment Rating Scale for Cocaine) administered weekly
Number of subjects: 147
Study: 6607603

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iothalamate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diatrizoate
Number of subjects: 60
Study: 3752434

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 28967554

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 615

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study: 27766596

Group type: EXPERIMENTAL
Intervention: Verum acupuncture (deep needling of specific points)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control acupuncture (superficial needling of non-acupuncture points)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both acupuncture treatments
Number of subjects: 53
Study: 24217938

Group type: EXPERIMENTAL
Intervention: Oral metformin (1,500 mg to 2,000 mg daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Increased insulin dose (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral metformin
Number of subjects: 90
Study: 23777757

Group type: EXPERIMENTAL
Intervention: MEG/FA data integration using jICA software
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lower FA values in bilateral posterior parietal regions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased FA in a right medial frontal region
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Right temporal, occipital and late central components
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall performance on the MATRICS
Number of subjects: 0
Study: 20364382

Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy and cytokine therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytokine therapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nephrectomy and subsequent metastasectomy
Number of subjects: 0
Study: 20063527

Group type: EXPERIMENTAL
Intervention: Adherence to the CONSORT statement
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sequence generation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Allocation concealment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Implementation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Blinding
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sample size
Number of subjects: 33
Study: 16847636

Group type: EXPERIMENTAL
Intervention: Tamoxifen citrate (TMX) at a 20-mg dosage
Number of subjects: 66

Group type: COMPARATOR
Intervention: No ovulation-induction drugs (Control)
Number of subjects: 66
Study: 12787038

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroid therapy with prednisone (50 mg/day) followed by clobetasol ointment plus antimycotics
Number of subjects: 49

Group type: COMPARATOR
Intervention: Topical treatment with clobetasol plus antimycotics
Number of subjects: 49
Study: 11068775

Group type: EXPERIMENTAL
Intervention: Intermittent ATG (IATG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Daily ATG (DATG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (IATG and DATG)
Number of subjects: 56
Study: 8648371

Group type: EXPERIMENTAL
Intervention: Epirubicin (EPI) plus Lonidamine (LND)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Epirubicin (EPI)
Number of subjects: 207
Study: 1482264

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice a day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (no labetalol prescribed)
Number of subjects: 18
Study: 6094076

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ), 25 mg twice a day (group 1; n = 12)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg twice a day (group 2; n = 12)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enalapril, 10 mg twice a day, with HCTZ, 25 mg twice a day (group 3; n = 5)
Number of subjects: 29
Study: 31300571

Group type: EXPERIMENTAL
Intervention: Psychosocial concerns
Number of subjects: 109

Group type: COMPARATOR
Intervention: Medical priorities
Number of subjects: 109
Study: 30010704

Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and resistance training program) for 12 weeks
Number of subjects: 77

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 77
Study: 27749542

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 72
Study: 24534142

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg once daily (OD)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Budesonide 3 mg three times daily (TID)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg OD
Number of subjects: 471

Group type: COMPARATOR
Intervention: Budesonide 3 mg TID
Number of subjects: 471
Study: 23088451

Group type: EXPERIMENTAL
Intervention: Nominal alignment TKR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Outlier alignment TKR
Number of subjects: 80

Group type: COMPARATOR
Intervention: Femoral-tibial rotational mismatch
Number of subjects: 80
Study: 19617300

Group type: EXPERIMENTAL
Intervention: Group-based smoking cessation counselling (national model)
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation programme (newly developed)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: No referral ('do as usual')
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Group-based smoking cessation counselling
Number of subjects: 1518

Group type: EXPERIMENTAL
Intervention: Internet-based smoking cessation programme
Number of subjects: 1518
Study: 17387132

Group type: EXPERIMENTAL
Intervention: Tilarginine (1‐mg/kg bolus and 1‐mg/kg per hour 5‐hour infusion)
Number of subjects: 398
Study: 16229112

Group type: EXPERIMENTAL
Intervention: Test formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference formulation of fluoxetine hydrochloride (20 mg dispersible tablet)
Number of subjects: 30
Study: 12394962

Group type: EXPERIMENTAL
Intervention: Afternoon rest (duration, 2:31 ± 1:04 hrs) with opportunity for a nap (duration, 1:07 ± 0:26 hrs, n = 6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No afternoon rest
Number of subjects: 11
Study: 11603414

Group type: EXPERIMENTAL
Intervention: Human polyvalent immunoglobulin for intravenous administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of immunoglobulin and plasmapheresis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 0
Study: 8890204

Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine (1.5 x 10^8 CFU)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine (1.5 x 10^9 CFU)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine (1.2 x 10^6 CFU)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: CVD 1203 vaccine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1537265

Group type: EXPERIMENTAL
Intervention: Fasting state (no food intake)
Number of subjects: 10

Group type: COMPARATOR
Intervention: After eating three main and three in‐between meals
Number of subjects: 10
Study: 6321454

Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30618054

Group type: EXPERIMENTAL
Intervention: AZD4831 135 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AZD4831 405 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AZD4831 (all doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30354631

Group type: EXPERIMENTAL
Intervention: Ultrathin bioresorbable polymer sirolimus-eluting stent (BP-SES)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Thin durable polymer everolimus-eluting stent (DP-EES)
Number of subjects: 677
Study: 27782851

Group type: EXPERIMENTAL
Intervention: Anti-reflux catheter (ARC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard microcatheter
Number of subjects: 25
Study: 24662234

Group type: COMPARATOR
Intervention: Full range of motion (ROM) squat (F)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Full ROM with partial ROM squat (FP)
Number of subjects: 17
Study: 22497598

Group type: EXPERIMENTAL
Intervention: Ribosomal prophylaxis with Immucytal® (one tablet daily, 8 days a month for 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (same dosage for the same period)
Number of subjects: 100
Study: 20530452

Group type: EXPERIMENTAL
Intervention: Rifampicin-miconazole-loaded central venous catheter (CVC)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Standard central venous catheter (CVC)
Number of subjects: 223
Study: 18721465

Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Laparoscopic ileocolic resection
Number of subjects: 130
Study: 15796147

Group type: EXPERIMENTAL
Intervention: Icodextrin-based peritoneal dialysis fluid (IPDF)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Glucose-based peritoneal dialysis fluid (GPDF)
Number of subjects: 56
Study: 11921054

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (30 microg weekly intramuscular injections)
Number of subjects: 383
Study: 9926179

Group type: EXPERIMENTAL
Intervention: Rocuronium 1.0 mg/kg
Number of subjects: 349

Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 349
Study: 8647745

Group type: EXPERIMENTAL
Intervention: Middle latency responses of auditory evoked magnetic fields
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Equivalent current dipole sources
Number of subjects: 4
Study: 2186020

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5-2.0 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Imipramine (25-50 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study: 233174

Group type: EXPERIMENTAL
Intervention: Clostridium welchii type C beta toxoid
Number of subjects: 5030

Group type: COMPARATOR
Intervention: Tetanus toxoid (control)
Number of subjects: 5030
Study: 31713469

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Carbapenem long-lasting (4h) infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 100
Study: 31185950

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 12
Study: 28052588

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg by Prefilled Syringe‐UltraSafe Passive® Delivery System (PFS‐U)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sirukumab 50 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg by Prefilled Syringe‐SmartJect® Autoinjector (PFS‐AI)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Sirukumab 100 mg intravenous (IV) infusion
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg by PFS‐AI
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sirukumab (all doses)
Number of subjects: 144
Study: 25739844

Group type: EXPERIMENTAL
Intervention: Ankle and midfoot mobilization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stretching exercises and ultrasound
Number of subjects: 50
Study: 23573882

Group type: EXPERIMENTAL
Intervention: Transperitoneal laparoscopic adrenalectomy (TLA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Retroperitoneal laparoscopic adrenalectomy (RLA)
Number of subjects: 24
Study: 21991893

Group type: EXPERIMENTAL
Intervention: Cytisine
Number of subjects: 740
Study: 19799882

Group type: EXPERIMENTAL
Intervention: Acamprosate (1998 mg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 16963848

Group type: EXPERIMENTAL
Intervention: Twofold illumination PDT scheme (50+50 J/cm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard PDT regimen (50 J/cm)
Number of subjects: 16
Study: 15596567

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome factor score
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 119
Study: 11713920

Group type: EXPERIMENTAL
Intervention: Intravenous injection of atropine sulfate
Number of subjects: 4
Study: 9209205

Group type: EXPERIMENTAL
Intervention: Computer-generated guideline recommendations
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard encounter form
Number of subjects: 30
Study: 7904003

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Transdermal patch
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Intranasal spray
Number of subjects: 17703

Group type: EXPERIMENTAL
Intervention: Inhaled nicotine
Number of subjects: 17703

Group type: COMPARATOR
Intervention: Control interventions
Number of subjects: 17703
Study: 2923763

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg i.v. in 5% dextrose 20 ml
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 786352

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Practolol (120 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30789006

Group type: EXPERIMENTAL
Intervention: Eye-hand-decoupled task
Number of subjects: 62

Group type: COMPARATOR
Intervention: Direct interaction task
Number of subjects: 62
Study: 28551445

Group type: EXPERIMENTAL
Intervention: Multimodal pain regimen
Number of subjects: 138

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study: 25937373

Group type: EXPERIMENTAL
Intervention: Laparoscopic robot‐assisted radical prostatectomy (LRARP)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Open retropubic radical prostatectomy (ORP)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Both ORP and LRARP
Number of subjects: 304
Study: 23320650

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (4930 mg = 20 mmol magnesium) administered 60 min before and 6 hours after ERCP
Number of subjects: 502

Group type: COMPARATOR
Intervention: Placebo administered 60 min before and 6 hours after ERCP
Number of subjects: 502
Study: 21414125

Group type: EXPERIMENTAL
Intervention: HAL TURB (fluorescence-guided transurethral resection using hexaminolaevulinate)
Number of subjects: 233

Group type: COMPARATOR
Intervention: WL TURB (conventional transurethral resection in white light)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: HAL TURB
Number of subjects: 233

Group type: COMPARATOR
Intervention: WL TURB
Number of subjects: 233
Study: 19326367

Group type: EXPERIMENTAL
Intervention: Short-term response information used for adaptive randomization in survival trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian model using prior clinical information and dynamic updates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interim monitoring and final decision making based on survival outcomes
Number of subjects: 0
Study: 17890730

Group type: EXPERIMENTAL
Intervention: Low-dose INR self-management
Number of subjects: 2673

Group type: COMPARATOR
Intervention: Conventional INR control
Number of subjects: 2673
Study: 15481562

Group type: EXPERIMENTAL
Intervention: Low-intensity home-based physical therapy (once a week for 10 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (delayed intervention after 10 weeks)
Number of subjects: 20
Study: 11853284

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Hyalgan 2 ml/wk for 4 doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (2 ml of normal saline)
Number of subjects: 0
Study: 9763324

Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Butler 411)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B Plaque Remover-D7)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B Ultra Plaque Remover-D9) with different types of endrounding
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Braun/Oral-B D7 at 2800 rot/min) and D9 at 3600 rot/min
Number of subjects: 97
Study: 7825006

Group type: EXPERIMENTAL
Intervention: Dioctahedral smectite (DS) with rehydration
Number of subjects: 66

Group type: COMPARATOR
Intervention: Oral or intravenous rehydration (Control)
Number of subjects: 66
Study: 3254767

Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO) at 8 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO) at 16 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO) at 8 Hz, 12 Hz, and 16 Hz
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO)
Number of subjects: 12
Study: 31462117

Group type: EXPERIMENTAL
Intervention: Oral Tramadol 50 mg, 1 hour prior to the procedure
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 30088558

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 37

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 37
Study: 26881073

Group type: EXPERIMENTAL
Intervention: Post-PSG alveolar NO concentration (CANO) in OSA patients
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Pre-PSG alveolar NO concentration (CANO) in OSA patients
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CANO correlation with apnea-hypopnea index (AHI)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CANO correlation with nadir SpO2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: CANO value for screening OSA
Number of subjects: 82
Study: 23640072

Group type: EXPERIMENTAL
Intervention: AZD1446 80 mg qd
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: AZD1446 (80 mg tid, 80 mg qd, 10 mg tid)
Number of subjects: 79
Study: 24429244

Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF assay
Number of subjects: 221

Group type: COMPARATOR
Intervention: Smear microscopy
Number of subjects: 221

Group type: COMPARATOR
Intervention: Solid culture (Löwenstein-Jensen medium)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Liquid culture (Bactec MGIT960 system)
Number of subjects: 221
Study: 19847152

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2102
Study: 18376185

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 100
Study: 16342198

Group type: EXPERIMENTAL
Intervention: Short-wave electromagnetic fields (6-22 MHz) exposure before shut down
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Short-wave electromagnetic fields (6-22 MHz) exposure after shut down
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Short-wave electromagnetic fields (6-22 MHz) exposure after shut down in poor sleepers
Number of subjects: 54
Study: 12699447

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (5 mg/day, n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study: 10680191

Group type: EXPERIMENTAL
Intervention: Herbal remedies
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 9360565

Group type: EXPERIMENTAL
Intervention: Restraint position
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 15
Study: 8204673

Group type: EXPERIMENTAL
Intervention: Alcohol education program (4-hour duration)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intimate exposure group
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Social exposure group
Number of subjects: 66
Study: 2888509

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 161
Study: 31900204

Group type: EXPERIMENTAL
Intervention: Combination therapy of lopinavir/ritonavir and recombinant interferon-Î²1b with standard supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with standard supportive care
Number of subjects: 0
Study: 28823904

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-surgical intervention
Number of subjects: 28
Study: 27619968

Group type: EXPERIMENTAL
Intervention: Nurse Practitioners (NPs)
Number of subjects: 12092

Group type: COMPARATOR
Intervention: General Practitioners (GPs)
Number of subjects: 12092
Study: 26617907

Group type: EXPERIMENTAL
Intervention: Percutaneous microwave ablation
Number of subjects: 90

Group type: COMPARATOR
Intervention: Laparoscopic resection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 90
Study: 23610239

Group type: EXPERIMENTAL
Intervention: Aliskiren 2 mg/kg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Aliskiren 6 mg/kg
Number of subjects: 39
Study: 21362527

Group type: EXPERIMENTAL
Intervention: Coping skills training (CST) intervention: 16 weekly 30-minute telephone counseling sessions including motivational interviewing and individually tailored cognitive behavioral therapy.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Heart failure education (HFE) intervention: 16 weekly 30-minute telephone sessions including education and symptom monitoring.
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: CST intervention
Number of subjects: 200